Communicators

are winners!

More News

10.01.2022
Positive Safety Data from First Cohort of Phase I - Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
15.12.2021
Recce Pharmaceuticals: Patients to be Dosed in Phase I Intravenous Clinical Trial of RECCE® 327
07.12.2021
Recce Pharmaceuticals: Update on Phase I/II Clinical Trial for the Treatment of Burn Wound Infections
25.10.2021
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I Intravenous Clinical Trial of RECCE® 327
30.09.2021
RECCE® 327 Trial Registered in the Australian New Zealand Clinical Trials Registry for Phase I Intravenous Study in Humans
11.08.2021
Recce Pharmaceuticals Receives Entrepreneurs’ Programme Innovation Connections Grant
30.07.2021
Recce Pharmaceuticals Ltd.: Quarterly Cash Flow Statement & Operational Highlights
22.07.2021
Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives
22.07.2021
Anti-Viral Patent Granted in China for RECCE® Anti-Infectives
19.07.2021
RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria